Taiwan Liposome Company:
TLC is a clinical-stage specialty pharmaceutical company dedicated to the development and commercialization of novel nanomedicines that combine proprietary lipid-assembled drug delivery platforms with approved active pharmaceutical ingredients (APIs). TLC's extensive experience with liposome science allows fast onset speed, prolonged benefit duration, and improved API concentrations at target tissues while decreasing unwanted systemic exposures. Product candidates span across pain (TLC599 for osteoarthritis pain (Ph2 complete, Ph3 mid-2019), TLC590 for postsurgical pain (reported Ph1/2 top line, Ph2 initiated)), ophthalmology (TLC399 for macular edema (Ph2)), and oncology (TLC178 for rhabdomyosarcoma (Ph1/2)). All programs expected to be in late or pivotal stage by the end of 2020.
Phase l or ll
Biotechnology, Specialty Pharmaceutical
100MM - 500MM
2F, 3 Yuanqu Street, Nangang District
Taipei , 11503
Send Message to Request Information
Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.
Stock Market Data
Market Data copyright © 2017 QuoteMedia.
Data delayed 15 minutes unless otherwise indicated (view
delay times for all
exchanges). RT=Real-Time, RTB=Real-Time
BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time
NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of
Day, PD=Previous Day. Market Data powered by